These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7555547)

  • 1. The effect of hyperglycemia on glipizide absorption in NIDDM patients.
    Esmatjes E; Vinuesa P; Navarro P; Rodriguez-Villar C; Gomis R; Vilardell E
    Diabetes Care; 1995 Jul; 18(7):1075-6. PubMed ID: 7555547
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus.
    Jaber LA; Ducharme MP; Halapy H
    Ther Drug Monit; 1996 Feb; 18(1):6-13. PubMed ID: 8848822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of glipizide treatment on response to an infused glucose load in patients with NIDDM.
    Sheu WH; Jeng CY; Fuh MM; Chen YD; Reaven GM
    Diabetes Care; 1995 Dec; 18(12):1582-7. PubMed ID: 8722055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM.
    Mooradian AD; Albert SG; Bernbaum M; Plummer S
    Diabetes Care; 1996 Aug; 19(8):883-4. PubMed ID: 8842609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM.
    Riddle MC; McDaniel PA; Tive LA
    Diabetes Care; 1997 Jun; 20(6):992-4. PubMed ID: 9167112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia.
    Bitzén PO; Melander A; Scherstén B; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1988; 35(1):31-7. PubMed ID: 3065086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses.
    Kradjan WA; Takeuchi KY; Opheim KE; Wood FC
    Pharmacotherapy; 1995; 15(4):465-71. PubMed ID: 7479199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
    Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
    Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes.
    Jönsson A; Chan JC; Rydberg T; Vaaler S; Hallengren B; Cockram CS; Critchley JA; Melander A
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):711-4. PubMed ID: 11214781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of immediate-release glipizide on hypoglycemic vulnerability in fasted, elderly patients with type 2 diabetes.
    Burge MR; Schmitz-Fiorentino K; Sood V; Schade DS
    JAMA; 1999 Mar 24-31; 281(12):1084-5. PubMed ID: 10188656
    [No Abstract]   [Full Text] [Related]  

  • 11. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
    Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
    Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic effects of combination glipizide and human proinsulin treatment in NIDDM.
    Pasmantier R; Chaiken RL; Hirsch SR; Lebovitz HE
    Diabetes Care; 1990 Aug; 13 Suppl 3():42-6. PubMed ID: 2209343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glipizide does not affect absorption of glucose and xylose in diabetics without residual beta-cell function.
    Lins PE; Kollind M; Adamson U
    Acta Med Scand; 1986; 219(2):189-93. PubMed ID: 3515865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance.
    Levy J; Vandenberg M; Grunberger G
    Am J Hypertens; 1995 May; 8(5 Pt 1):445-53. PubMed ID: 7662219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentially important contribution of dextrose used as diluent to hyperglycemia in hospitalized patients.
    Krajicek BJ; Kudva YC; Hurley HA
    Diabetes Care; 2005 Apr; 28(4):981-2. PubMed ID: 15793213
    [No Abstract]   [Full Text] [Related]  

  • 16. The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association.
    Diabetes Care; 1995 Nov; 18(11):1510-8. PubMed ID: 8722084
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.
    Kim NT; Cho CK; Kang P; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
    Arch Pharm Res; 2022 Feb; 45(2):114-121. PubMed ID: 34952963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of intensive blood glucose control with hypoglycemic sulfamides, metformin or insulin on complications of non-insulin dependent diabetes].
    André P
    Rev Epidemiol Sante Publique; 1999 Mar; 47(1):93-5. PubMed ID: 10214683
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats.
    Bennett N; Papich MG; Hoenig M; Fettman MJ; Lappin MR
    Am J Vet Res; 2005 Apr; 66(4):581-8. PubMed ID: 15900936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of glucose-primed intravenous glucose tolerance and correction of acute insulin decrement by glipizide in type II diabetes.
    Ravanam A; Jeffery J; Nehlawi M; Abraira C
    Metabolism; 1991 Nov; 40(11):1173-7. PubMed ID: 1943745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.